As the global spread of COVID-19 has put Korea's bio and medical sectors in the spotlight, representative bio-venture companies engaged in new drug R&D located in Songdo International City, Incheon Free Economic Zone (IFEZ), are drawing attention.
The CEOs of these companies have a strong will to become the world's best, presenting new paradigms through new drug development and building partnerships with globally recognized top institutions, contributing greatly to making Songdo — which is leaping forward as a global bio cluster — a home for bio ventures.
We can meet RudaCure, a young venture founded in 2018 by a 36-year-old young professor. CEO Yongho Kim emphasizes that pain is not just a symptom but a disease requiring treatment, and is at the forefront of developing treatments.
He received the '2020 Korea's Person Opening the Future Award' for his contribution to presenting a new paradigm in Korea's new drug development industry and enhancing the competitiveness of the bio industry.
RudaCure, together with Bundang CHA Hospital, is jointly developing a treatment for spinal diseases, combining stem cell regenerative technology and pain control technology.